17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, Brazil
Ana Carolina Campi-Azevedo
, Vanessa Peruhype-Magalhāes, Jordana Grazziela Coelho-dos-Reis, Lis Ribeiro Antonelli, Christiane Costa-Pereira, Elaine Speziali, Laise Rodrigues Reis, Jandira Aparecida Lemos, José Geraldo Leite Ribeiro, Luiz Antônio Bastos Camacho, Maria de Lourdes de Sousa Maia, Sheila Maria Barbosa de Lima, Marisol Simões, Reinaldo de Menezes Martins, Akira Homma, Luiz Cosme Cota Malaquias, Pedro Luiz Tauil, Pedro Fernando Costa Vasconcelos, Alessandro Pecego Martins Romano, Carla Magda Domingues, Andréa Teixeira-Carvalho, Olindo Assis Martins-Filho
, and Collaborative Group for Studies of Yellow Fever Vaccine
Author affiliations: Instituto René Rachou of Fundação Oswaldo Cruz (FIOCRUZ-Minas),; Belo Horizonte, Brazil (A.C. Campi-Azevedo, V. Peruhype-Magalhāes, J.G. Coelho-dos-Reis, L.R. Antonelli, C. Costa-Pereira, E. Speziali, L.R. Reis, A. Teixeira-Carvalho, O.A. Martins-Filho); Universidade Federal de Minas Gerais, Belo Horizonte (J.G. Coelho-dos-Reis); Secretaria Municipal de Saúde, Belo Horizonte (J.A. Lemos); Secretaria do Estado de Saúde de Minas Gerais, Belo Horizonte (J.G.L. Ribeiro); Escola Nacional de Saúde Pública (FIOCRUZ-Rio), Rio de Janeiro, Brazil (L.A.B. Camacho); Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos (FIOCRUZ-Rio),; Rio de Janeiro (M. de Lourdes de Sousa Maia, S.M. Barbosa de Lima, M. Simões, R. de Menezes Martins, A. Homma); Universidade Federal de Alfenas, Alfenas, Brazil (L.C.C. Malaquias); Universidade de Brasília, Brasília, Brazil (P.L. Tauil); Instituto Evandro Chagas, Ananindeua, Brazil (P.F.C. Vasconcelos); Secretaria de Vigilância em Saúde—Ministério da Saúde, Brasília (A.P.M. Romano, C.M. Domingues)
Main Article
Figure 6
Figure 6. Overall proportion of participants with resultant memory before and after primary or secondary 17DD vaccination for YF as assessed by PRNT and EMCD8 measurement at participant level. Graphs show the proportion of participants above the cutoff threshold; that is, PRNT positivity at serum dilution >1:50 and EMCD8 index above the global median value. We then determined the resultant memory for each subgroup in the primary vaccination arm (A) and secondary vaccination (B) of the study. Participant subgroups indicate number of days or years since vaccination (in parentheses; d0 for those never vaccinated). Lowercase letters indicate significant differences (p<0.05 by χ2 test) of resultant memory status among study groups: a for comparisons with NV(d0) participants; b for comparisons with PV(d30–45) participants; c for comparison with PV(y1–5) participants; and d for comparison with #PV(y>10) participants. #PV, had primary vaccination >10 years previously; NV, not vaccinated; PRNT, plaque-reducing neutralization test; PV, had primary vaccination only; RV, revaccinated; YF, yellow fever.
Main Article
Page created: July 16, 2019
Page updated: July 16, 2019
Page reviewed: July 16, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.